Medication Profile—Community Hospital
Date of admission: 7/15
Patient Name: William Rivera
Race: Hispanic
Address: 1136 Nowhere St.
Height: 5'7”
Age: 55
Weight: 162 lb
Gender: M
Allergies: Penicillin

Diagnosis
Primary: Pulmonary edema secondary to CHF  
Secondary: Stroke, depression, hypercholesterolemic, anxiety, atrial fib, hypertension, constipation, urinary retention

Admission orders
 
Date
Name and Strength
Route
Sig
1.
7/15
Protonix®
PO
i qd
2.
7/15
Flomax® 0.8
PO
i qd
3.
7/15
CelexaTM 20 mg
PO
i qd
4.
7/15
Zocor® 20 mg
PO
i qhs
5.
7/15
Tums®
PO
i bid
6.
7/15
Xanax® 1 mg
PO
i bid
7.
7/15
Lactulose 20 g
PO
i am
8.
7/15
ASA 81 mg
PO
i qd
9.
7/15
Lopressor® 12.5 mg
PO
i bid
10.
7/15
Altace® 20 mg
PO
i qd
11.
7/15
Lasix® 20 mg
PO
i qd
12.
7/15
Zyprexa® 12.5 mg
PO
i qhs
13.
7/15
Oramorph® 60 mg
PO
i qam
14.
7/15
Oramorph® 30 mg
PO
i qpm
15.
7/15
Tylenol® 325 mg
PO
i 1-2 q4-6h prn
16.
7/15
Milk of magnesia 30cc
PO
i qd prn
17.
7/15
Dulcolax® supp
PR
i prn

Dietary considerations
Date
1.
7/15
Honey, thickened liquids
 
Use the patient profile above to answer the following questions.

1.
Which of the drugs listed for Mr. Rivera is being used to treat his urinary retention?
A.
CelexaTM
B.
Flomax®
C.
Zocor®
D.
Altace®
E.
Zyprexa®


2.
How many of the drugs listed in Mr. Rivera's medication profile are indicated to treat his hypertension?
A.
1
B.
3
C.
5
D.
6
E.
8


3.
The beneficial effects of Na+ and water retention in congestive heart failure include
I. Optimization of stroke volume via the Frank-Starling mechanism
II. Increase in sympathetic venous system activity
III. Ventricular hypertrophy
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


4.
Which of the following agents is a drug that is commonly used, as a prophylaxis in stroke, but has not been included in the medication profile for this patient?
A.
Indocin®
B.
Coumadin®
C.
Lanoxin®
D.
Lasix®
E.
Hep-Lock


5.
Which of the drugs listed in Mr. Rivera's profile inhibits the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis?
A.
Protonix®
B.
Flomax®
C.
CelexaTM
D.
Zocor®
E.
Xanax®


6.
Beta-adrenergic blockers listed in Mr. Rivera's medication profile include
I. Altace®
II. Lopressor®
III. Lasix®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


7.
Which of the drugs that Mr. Rivera is taking will help him relieve dyspnea of pulmonary edema
I. Zyprexa®
II. Lopressor®
III. Oramorph®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


8.
Which of the following agents could be used as adjunct therapy if his antilipemic agent did not prove effective in reducing serum cholesterol levels to desired levels?
A.
Pepcid®
B.
Plavix®
C.
TriCor®
D.
Colchicine
E.
Cozaar®


9.
At what LDL serum level should an antilipemic therapy be initiated on a patient with a history of coronary heart disease?
A.
> 80 mg/dL
B.
> 90 mg/dL
C.
> 100 mg/dL
D.
> 130 mg/dL
E.
> 160 mg/dL


10.
Factors that are considered risk factors for atherosclerotic disease include
I. Actively smoking cigarettes
II. Diabetes mellitus
III. Hypertension or taking antihypertensive medications
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


STOP This is the end of the test. When you have completed all the questions and reviewed your answers, press the button below to grade the test.